QQQ   432.79 (+0.19%)
AAPL   188.32 (-0.58%)
MSFT   414.11 (+0.01%)
META   470.00 (+0.09%)
GOOGL   145.91 (+0.25%)
AMZN   169.84 (-0.40%)
TSLA   189.56 (+1.06%)
NVDA   696.41 (-0.65%)
NIO   5.82 (-0.68%)
AMD   169.35 (-0.93%)
BABA   70.74 (-3.94%)
T   16.82 (-2.94%)
F   12.83 (+0.23%)
MU   84.88 (-0.34%)
CGC   4.11 (-4.86%)
GE   139.07 (+0.41%)
DIS   110.54 (+11.50%)
AMC   4.09 (+3.81%)
PFE   27.56 (+0.00%)
PYPL   56.13 (-11.24%)
XOM   103.97 (+1.71%)
QQQ   432.79 (+0.19%)
AAPL   188.32 (-0.58%)
MSFT   414.11 (+0.01%)
META   470.00 (+0.09%)
GOOGL   145.91 (+0.25%)
AMZN   169.84 (-0.40%)
TSLA   189.56 (+1.06%)
NVDA   696.41 (-0.65%)
NIO   5.82 (-0.68%)
AMD   169.35 (-0.93%)
BABA   70.74 (-3.94%)
T   16.82 (-2.94%)
F   12.83 (+0.23%)
MU   84.88 (-0.34%)
CGC   4.11 (-4.86%)
GE   139.07 (+0.41%)
DIS   110.54 (+11.50%)
AMC   4.09 (+3.81%)
PFE   27.56 (+0.00%)
PYPL   56.13 (-11.24%)
XOM   103.97 (+1.71%)
QQQ   432.79 (+0.19%)
AAPL   188.32 (-0.58%)
MSFT   414.11 (+0.01%)
META   470.00 (+0.09%)
GOOGL   145.91 (+0.25%)
AMZN   169.84 (-0.40%)
TSLA   189.56 (+1.06%)
NVDA   696.41 (-0.65%)
NIO   5.82 (-0.68%)
AMD   169.35 (-0.93%)
BABA   70.74 (-3.94%)
T   16.82 (-2.94%)
F   12.83 (+0.23%)
MU   84.88 (-0.34%)
CGC   4.11 (-4.86%)
GE   139.07 (+0.41%)
DIS   110.54 (+11.50%)
AMC   4.09 (+3.81%)
PFE   27.56 (+0.00%)
PYPL   56.13 (-11.24%)
XOM   103.97 (+1.71%)
QQQ   432.79 (+0.19%)
AAPL   188.32 (-0.58%)
MSFT   414.11 (+0.01%)
META   470.00 (+0.09%)
GOOGL   145.91 (+0.25%)
AMZN   169.84 (-0.40%)
TSLA   189.56 (+1.06%)
NVDA   696.41 (-0.65%)
NIO   5.82 (-0.68%)
AMD   169.35 (-0.93%)
BABA   70.74 (-3.94%)
T   16.82 (-2.94%)
F   12.83 (+0.23%)
MU   84.88 (-0.34%)
CGC   4.11 (-4.86%)
GE   139.07 (+0.41%)
DIS   110.54 (+11.50%)
AMC   4.09 (+3.81%)
PFE   27.56 (+0.00%)
PYPL   56.13 (-11.24%)
XOM   103.97 (+1.71%)

Pharmaceutical Stocks List

Compare pharmaceutical stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Learn more about trading pharmaceutical stocks.

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Moderna, Inc. stock logo
MRNA
Moderna
$93.66
-5.7%
$96.15
$62.55
$177.37
$35.71B1.694.51 million shs4.91 million shs
AbbVie Inc. stock logo
ABBV
AbbVie
$174.79
-0.1%
$158.60
$130.96
$175.91
$314.62B0.575.60 million shs5.51 million shs
Bristol-Myers Squibb stock logo
BMY
Bristol-Myers Squibb
$48.71
+0.1%
$50.54
$47.58
$73.84
$99.11B0.3816.32 million shs13.57 million shs
GSK plc stock logo
GSK
GSK
$41.82
-0.5%
$38.28
$33.20
$42.21
$86.05B0.643.81 million shs4.30 million shs
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
$156.43
-1.0%
$158.20
$144.95
$175.97
$376.56B0.537.09 million shs9.75 million shs
McKesson Co. stock logo
MCK
McKesson
$494.23
-4.4%
$473.90
$331.75
$519.75
$65.76B0.44792,185 shs2.26 million shs
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
$126.61
-0.7%
$113.66
$99.14
$128.06
$320.83B0.388.18 million shs6.31 million shs
Pfizer Inc. stock logo
PFE
Pfizer
$27.56
$28.28
$25.76
$44.33
$155.59B0.6246.07 million shs29.01 million shs
XPH
SPDR S&P Pharmaceuticals ETF
$43.33
+0.8%
$41.10
$34.67
$44.31
$227.49M0.8451,428 shs11,665 shs
13 Stocks Institutional Investors Won't Stop Buying Cover

Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Moderna, Inc. stock logo
MRNA
Moderna
-0.73%-1.73%-13.98%+42.86%-41.95%
AbbVie Inc. stock logo
ABBV
AbbVie
+1.01%+6.49%+8.42%+26.79%+20.59%
Bristol-Myers Squibb stock logo
BMY
Bristol-Myers Squibb
-1.28%-0.49%-6.07%-3.53%-34.74%
GSK plc stock logo
GSK
GSK
+0.65%+6.54%+5.99%+21.89%+16.16%
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
-0.06%-0.58%-2.19%+7.20%-3.32%
McKesson Co. stock logo
MCK
McKesson
+1.99%+3.42%+8.47%+11.93%+42.18%
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
+0.47%+5.54%+8.60%+24.49%+20.62%
Pfizer Inc. stock logo
PFE
Pfizer
+0.18%+1.85%-6.84%-7.11%-36.77%
XPH
SPDR S&P Pharmaceuticals ETF
-1.22%+2.31%+0.16%+21.83%-2.50%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Moderna, Inc. stock logo
MRNA
Moderna
4.3122 of 5 stars
4.12.00.04.61.73.30.0
AbbVie Inc. stock logo
ABBV
AbbVie
4.8815 of 5 stars
2.33.04.23.93.72.52.5
Bristol-Myers Squibb stock logo
BMY
Bristol-Myers Squibb
4.9597 of 5 stars
3.13.05.04.03.03.31.9
GSK plc stock logo
GSK
GSK
1.9086 of 5 stars
0.03.02.50.03.00.01.9
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
4.913 of 5 stars
3.23.04.23.93.71.71.9
McKesson Co. stock logo
MCK
McKesson
4.7252 of 5 stars
2.43.03.33.03.02.52.5
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
4.5118 of 5 stars
2.43.03.34.22.62.51.3
Pfizer Inc. stock logo
PFE
Pfizer
4.9992 of 5 stars
4.23.04.24.82.43.33.1
XPH
SPDR S&P Pharmaceuticals ETF
N/AN/AN/AN/AN/AN/AN/AN/A

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Moderna, Inc. stock logo
MRNA
Moderna
2.12
Hold$123.9632.35% Upside
AbbVie Inc. stock logo
ABBV
AbbVie
2.56
Moderate Buy$171.47-1.90% Downside
Bristol-Myers Squibb stock logo
BMY
Bristol-Myers Squibb
2.11
Hold$61.1725.57% Upside
GSK plc stock logo
GSK
GSK
2.40
HoldN/AN/A
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
2.38
Hold$176.1412.61% Upside
McKesson Co. stock logo
MCK
McKesson
2.80
Moderate Buy$507.312.65% Upside
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
2.76
Moderate Buy$129.682.43% Upside
Pfizer Inc. stock logo
PFE
Pfizer
2.33
Hold$36.9334.03% Upside
XPH
SPDR S&P Pharmaceuticals ETF
0.00
N/A$79.7784.10% Upside

Current Analyst Ratings

Latest Pharmaceutical Stocks Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
2/8/2024
McKesson Co. stock logo
MCK
McKesson
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$530.00 ➝ $575.00
2/6/2024
AbbVie Inc. stock logo
ABBV
AbbVie
Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$180.00 ➝ $195.00
2/6/2024
Bristol-Myers Squibb stock logo
BMY
Bristol-Myers Squibb
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetEqual Weight ➝ Equal Weight$58.00 ➝ $51.00
2/6/2024
Bristol-Myers Squibb stock logo
BMY
Bristol-Myers Squibb
Redburn Atlantic
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeBuy ➝ Neutral$77.00 ➝ $54.00
2/6/2024
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$215.00
2/5/2024
AbbVie Inc. stock logo
ABBV
AbbVie
BMO Capital Markets
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$187.00 ➝ $195.00
2/5/2024
AbbVie Inc. stock logo
ABBV
AbbVie
Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$175.00 ➝ $185.00
2/5/2024
AbbVie Inc. stock logo
ABBV
AbbVie
Raymond James
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$181.00 ➝ $189.00
2/5/2024
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$135.00
2/2/2024
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$122.00 ➝ $139.00
2/2/2024
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$135.00 ➝ $148.00
(Data available from 2/8/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Moderna, Inc. stock logo
MRNA
Moderna
$19.26B1.85$21.29 per share4.40$49.78 per share1.88
AbbVie Inc. stock logo
ABBV
AbbVie
$54.32B5.79$18.86 per share9.27$9.78 per share17.87
Bristol-Myers Squibb stock logo
BMY
Bristol-Myers Squibb
$45.01B2.20$11.97 per share4.07$14.64 per share3.33
GSK plc stock logo
GSK
GSK
$37.71B2.28$4.47 per share9.36$5.79 per share7.22
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
$85.16B4.42$12.87 per share12.15$29.39 per share5.32
McKesson Co. stock logo
MCK
McKesson
$276.71B0.24$31.42 per share15.73($10.99) per share-44.97
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
$60.12B5.34$9.02 per share14.04$18.17 per share6.97
Pfizer Inc. stock logo
PFE
Pfizer
$58.50B2.66$2.71 per share10.18$17.09 per share1.61
XPH
SPDR S&P Pharmaceuticals ETF
N/AN/AN/AN/AN/AN/A

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Moderna, Inc. stock logo
MRNA
Moderna
$8.36B-$9.35N/AN/AN/A-38.00%-2.14%-1.60%2/22/2024 (Confirmed)
AbbVie Inc. stock logo
ABBV
AbbVie
$4.86B$2.7364.0314.352.208.95%154.73%14.60%4/25/2024 (Estimated)
Bristol-Myers Squibb stock logo
BMY
Bristol-Myers Squibb
$8.03B$3.8612.626.751.4217.83%50.33%16.77%4/25/2024 (Estimated)
GSK plc stock logo
GSK
GSK
$6.13B$3.0113.899.771.8316.24%52.25%10.55%4/24/2024 (Estimated)
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
$35.15B$13.8111.3314.222.6537.79%36.75%14.50%4/16/2024 (Estimated)
McKesson Co. stock logo
MCK
McKesson
$3.56B$25.3119.5315.891.771.20%-241.79%5.95%5/13/2024 (Estimated)
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
$365M$0.14904.3613.221.640.61%9.07%3.61%4/25/2024 (Estimated)
Pfizer Inc. stock logo
PFE
Pfizer
$2.12B$0.3676.549.951.223.62%10.61%5.01%5/7/2024 (Estimated)
XPH
SPDR S&P Pharmaceuticals ETF
N/AN/A10.11N/AN/AN/AN/AN/A

Latest Pharmaceutical Stocks Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
2/22/2024N/A
Moderna, Inc. stock logo
MRNA
Moderna
-$0.82N/A+$0.82N/AN/AN/A  
2/7/2024Q3 2024
McKesson Co. stock logo
MCK
McKesson
$7.05$7.74+$0.69$11.06$77.93 billion$80.90 billion    
2/2/202412/31/2023
AbbVie Inc. stock logo
ABBV
AbbVie
$2.76$2.79+$0.03$5.12$14.02 billion$14.30 billion    
2/2/202412/31/2023
Bristol-Myers Squibb stock logo
BMY
Bristol-Myers Squibb
$1.55$1.70+$0.15$2.53$11.19 billion$11.48 billion    
2/1/2024Q4 2023
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
-$0.09$0.03+$0.12$0.54$14.49 billion$14.63 billion    
1/30/202412/31/2023
Pfizer Inc. stock logo
PFE
Pfizer
-$0.19$0.10+$0.29$0.80$14.37 billion$14.25 billion    
1/23/202412/31/2023
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
$2.28$2.29+$0.01$2.91$21.02 billion$21.40 billion    

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Moderna, Inc. stock logo
MRNA
Moderna
N/AN/AN/AN/AN/A
AbbVie Inc. stock logo
ABBV
AbbVie
$6.203.55%+7.84%227.11%52 Years
Bristol-Myers Squibb stock logo
BMY
Bristol-Myers Squibb
$2.404.93%+8.20%62.18%15 Years
GSK plc stock logo
GSK
GSK
$1.403.35%-18.20%46.51%1 Years
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
$4.763.04%+5.70%34.47%62 Years
McKesson Co. stock logo
MCK
McKesson
$2.480.50%+11.80%9.80%16 Years
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
$3.082.43%+6.08%2,200.00%13 Years
Pfizer Inc. stock logo
PFE
Pfizer
$1.686.10%+12.89%466.67%14 Years
XPH
SPDR S&P Pharmaceuticals ETF
$0.671.55%N/AN/AN/A

Latest Pharmaceutical Stocks Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
2/1/2024
GSK plc stock logo
GSK
GSK
quarterly$0.35643.4%2/22/20242/23/20244/11/2024
1/23/2024
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
quarterly$0.772.6%3/14/20243/15/20244/5/2024
2/1/2024
McKesson Co. stock logo
MCK
McKesson
quarterly$0.620.5%2/29/20243/1/20244/1/2024
1/2/2024
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
quarterly$1.193.03%2/16/20242/20/20243/5/2024
12/14/2023
Pfizer Inc. stock logo
PFE
Pfizer
quarterly$0.426.43%1/25/20241/26/20243/1/2024
12/6/2023
Bristol-Myers Squibb stock logo
BMY
Bristol-Myers Squibb
quarterly$0.604.81%1/4/20241/5/20242/1/2024
11/28/2023
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
quarterly$0.773%12/14/202312/15/20231/8/2024
(Data available from 1/1/2013 forward)

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Moderna, Inc. stock logo
MRNA
Moderna
0.04
2.46
2.35
AbbVie Inc. stock logo
ABBV
AbbVie
4.59
0.96
0.84
Bristol-Myers Squibb stock logo
BMY
Bristol-Myers Squibb
1.11
1.18
1.07
GSK plc stock logo
GSK
GSK
1.27
0.95
0.70
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
0.37
1.21
0.96
McKesson Co. stock logo
MCK
McKesson
N/A
0.93
0.50
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
0.82
1.38
1.12
Pfizer Inc. stock logo
PFE
Pfizer
0.63
2.38
2.05
XPH
SPDR S&P Pharmaceuticals ETF
N/AN/AN/A

Ownership

Institutional Ownership

CompanyInstitutional Ownership
Moderna, Inc. stock logo
MRNA
Moderna
64.51%
AbbVie Inc. stock logo
ABBV
AbbVie
67.86%
Bristol-Myers Squibb stock logo
BMY
Bristol-Myers Squibb
74.98%
GSK plc stock logo
GSK
GSK
13.53%
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
68.40%
McKesson Co. stock logo
MCK
McKesson
82.69%
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
74.59%
Pfizer Inc. stock logo
PFE
Pfizer
68.05%
XPH
SPDR S&P Pharmaceuticals ETF
N/A

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Moderna, Inc. stock logo
MRNA
Moderna
3,900381.28 million321.42 millionOptionable
AbbVie Inc. stock logo
ABBV
AbbVie
50,0001.80 billion1.80 billionOptionable
Bristol-Myers Squibb stock logo
BMY
Bristol-Myers Squibb
34,3002.03 billion2.03 billionOptionable
GSK plc stock logo
GSK
GSK
69,4002.06 billion1.85 billionOptionable
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
155,8002.41 billion2.40 billionOptionable
McKesson Co. stock logo
MCK
McKesson
51,000133.06 million132.78 millionOptionable
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
69,0002.53 billion2.53 billionOptionable
Pfizer Inc. stock logo
PFE
Pfizer
83,0005.65 billion5.64 billionOptionable
XPH
SPDR S&P Pharmaceuticals ETF
N/A5.25 millionN/ANot Optionable

Pharmaceutical Stocks Headlines

SourceHeadline
Pharmaceutical Stocks - Best Pharmaceutical Stocks to Buy (XPH)Pharmaceutical Stocks - Best Pharmaceutical Stocks to Buy (XPH)
marketbeat.com - February 5 at 4:59 PM
S&P 500 (SPX) today: Catalent Inc is a top mover, up 10%S&P 500 (SPX) today: Catalent Inc is a top mover, up 10%
usatoday.com - February 5 at 1:21 PM
SPDR S&P Pharmaceuticals ETF (ARCA:XPH), Quotes and News SummarySPDR S&P Pharmaceuticals ETF (ARCA:XPH), Quotes and News Summary
benzinga.com - December 23 at 9:49 AM
SPDR S&P Pharmaceuticals ETF declares quarterly distribution of $0.1744SPDR S&P Pharmaceuticals ETF declares quarterly distribution of $0.1744
msn.com - December 18 at 5:56 PM
Why the S&P 500 ETF’s rare triple ‘gap ups’ isn’t a buy signalWhy the S&P 500 ETF’s rare triple ‘gap ups’ isn’t a buy signal
marketwatch.com - November 6 at 3:52 PM
XPH ETF Stock Price HistoryXPH ETF Stock Price History
investing.com - October 29 at 9:43 AM
ETF Watch: Fortitude, Not Fashion Wins OutETF Watch: Fortitude, Not Fashion Wins Out
thestreet.com - October 20 at 7:32 AM
SPDR Portfolio Mid Cap ETF declares quarterly distribution of $0.1758SPDR Portfolio Mid Cap ETF declares quarterly distribution of $0.1758
msn.com - September 18 at 1:00 PM
How Much Pain Will Lower Medicare Prices Cause for Pharma Stocks? (XPH)How Much Pain Will Lower Medicare Prices Cause for Pharma Stocks? (XPH)
marketbeat.com - September 1 at 7:00 AM
What is behind big pharmas underperformance?What is behind big pharma's underperformance?
msn.com - June 25 at 3:32 PM
SPDR S&P Pharmaceuticals ETF declares quarterly distribution of $0.1235SPDR S&P Pharmaceuticals ETF declares quarterly distribution of $0.1235
msn.com - June 21 at 9:19 AM
SPY ETF Gains 11% YTD: Technical Indicators Signal Further UpsideSPY ETF Gains 11% YTD: Technical Indicators Signal Further Upside
markets.businessinsider.com - May 31 at 10:15 PM
When Spdr S&p Pharmaceuticals ($XPH) Moves Investors should ListenWhen Spdr S&p Pharmaceuticals ($XPH) Moves Investors should Listen
marketwatch.com - April 12 at 3:10 PM
XPH SPDR S&P Pharmaceuticals ETFXPH SPDR S&P Pharmaceuticals ETF
seekingalpha.com - March 22 at 7:10 PM
SPYV: How Microsoft And Amazon Changed The S&P 500 Value IndexSPYV: How Microsoft And Amazon Changed The S&P 500 Value Index
seekingalpha.com - January 3 at 1:19 PM
Eli Lilly: Right Industry, Wrong PriceEli Lilly: Right Industry, Wrong Price
seekingalpha.com - December 27 at 2:36 PM
SPDR S&P Pharmaceuticals ETF declares quarterly distribution of $0.1940SPDR S&P Pharmaceuticals ETF declares quarterly distribution of $0.1940
msn.com - December 19 at 5:47 PM
SPDR S&P 500 ESG ETF declares quarterly distribution of $0.1728SPDR S&P 500 ESG ETF declares quarterly distribution of $0.1728
msn.com - December 16 at 2:04 PM
XPH: U.S. Pharmaceuticals Stocks Are Probably Fairly Valued, Cyclically UnattractiveXPH: U.S. Pharmaceuticals Stocks Are Probably Fairly Valued, Cyclically Unattractive
seekingalpha.com - November 13 at 3:57 AM
Chevron, Uber Technologies, And A Way To Bet Against The Big Guys Are CNBCs Final TradesChevron, Uber Technologies, And A Way To 'Bet Against The Big Guys' Are CNBC's 'Final Trades'
msn.com - November 2 at 7:47 PM
Discerning Dealmaking: Caution Flag Still Raised in Biopharma M&A RaceDiscerning Dealmaking: Caution Flag Still Raised in Biopharma M&A Race
pharmexec.com - October 11 at 7:03 PM
MDYG SPDR S&P 400 Mid Cap Growth ETFMDYG SPDR S&P 400 Mid Cap Growth ETF
seekingalpha.com - October 1 at 6:13 AM
SPDR S&P Pharmaceuticals ETF declares quarterly distribution of $0.1320SPDR S&P Pharmaceuticals ETF declares quarterly distribution of $0.1320
seekingalpha.com - September 21 at 4:56 AM
Drug ETFs Likely Winners of Health LawDrug ETFs Likely Winners of Health Law
thestreet.com - September 7 at 7:04 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

All Headlines

Company Descriptions

Moderna logo

Moderna

NASDAQ:MRNA
Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella-zoster virus, and human immunodeficiency virus vaccines; and public health vaccines consists of Zika and Nipah vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; localized regenerative, systemic intracellular, and inhaled pulmonary therapeutics. It has strategic alliances and collaborations with AstraZeneca; Merck; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Chiesi Farmaceutici S.p.A.; Metagenomi, Inc.; Carisma Therapeutics, Inc.; CytomX Therapeutics; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation, as well as a strategic partnership with Caris Life Sciences to advance mRNA-Based oncology therapeutics. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.
AbbVie logo

AbbVie

NYSE:ABBV
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, a therapy administered as an injection for autoimmune, intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq, a JAK inhibitor to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, and ulcerative colitis; Imbruvica for the treatment of adult patients with blood cancers; and Venclexta/Venclyxto to treat hematological malignancies. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; and Ubrelvy for the acute treatment of migraine with or without aura in adults; Qulipta for episodic migraine. In addition, the company offers Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure(IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Restasis, a calcineurin inhibitor immunosuppressant indicated to increase tear production; and eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus (HCV) genotype 1-6 infection and HCV genotype 1 infection; Creon, a pancreatic enzyme therapy; Lupron to treat advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid for hypothyroidism. It has collaborations with Calico Life Sciences LLC; REGENXBIO Inc.; I-Mab Biopharma; Genmab A/S; Janssen Biotech, Inc.; Genentech, Inc.; California Institute for Biomedical Research (Calibr), and BigHat Biosciences, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Bristol-Myers Squibb logo

Bristol-Myers Squibb

NYSE:BMY
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis, an oral inhibitor for reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; Opdivo for anti-cancer indications; Pomalyst/Imnovid indicated for patients with multiple myeloma; Orencia for adult patients with active RA and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia. It also provides Yervoy for the treatment of patients with unresectable or metastatic melanoma; Empliciti for the treatment of multiple myeloma; Abecma for the treatment of relapsed or refractory multiple myeloma; Reblozyl for the treatment of anemia in adult patients with beta thalassemia; Opdualag for the treatment of unresectable or metastatic melanoma; and Zeposia to treat relapsing forms of multiple sclerosis. In addition, the company offers Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma; Onureg for the treatment of adult patients with AML; Inrebic, an oral kinase inhibitor indicated for the treatment of myelofibrosis; Camzyos for the treatment of adults with symptomatic obstructive HCM to enhance functional capacity and symptoms; Sotyktu for the treatment of adults with moderate-to-severe plaque psoriasis; Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; and Abraxane, a protein-bound chemotherapy product. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in New York, New York.
GSK logo

GSK

NYSE:GSK
GSK plc, together with its subsidiaries, engages in the research, development and manufacture of vaccines and specialty medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as infectious disease, HIV, immunology and respiratory, and oncology. The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is based in Brentford, the United Kingdom.
Johnson & Johnson logo

Johnson & Johnson

NYSE:JNJ
Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment provides skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; TYLENOL acetaminophen products; SUDAFED cold, flu, and allergy products; BENADRYL and ZYRTEC allergy products; MOTRIN IB ibuprofen products; NICORETTE smoking cessation products; and PEPCID acid reflux products. This segment also offers STAYFREE and CAREFREE sanitary pads; o.b. tampons; adhesive bandages under the BAND-AID brand; and first aid products under the NEOSPORIN brand. It serves general public, retail outlets, and distributors. The company's Pharmaceutical segment provides products for rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; HIV/AIDS infectious diseases; mood disorders, neurodegenerative disorders, and schizophrenia; prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; thrombosis, diabetes, and macular degeneration; and pulmonary arterial hypertension. This segment serves retailers, wholesalers, distributors, hospitals, and healthcare professionals directly for prescription use. Its MedTech segment offers electrophysiology products to treat cardiovascular diseases; neurovascular care products to treat hemorrhagic and ischemic stroke; orthopaedics products in support of hips, knees, trauma, spine, sports, and other; advanced and general surgery solutions that focus on breast aesthetics, ear, nose, and throat procedures; and contact lenses and ophthalmic technologies related to cataract and laser refractive surgery under the ACUVUE brand. This segment serves wholesalers, hospitals, and retailers. Johnson & Johnson was founded in 1886 and is based in New Brunswick, New Jersey.
McKesson logo

McKesson

NYSE:MCK
McKesson Corporation provides healthcare services in the United States and internationally. It operates through four segments: U.S. Pharmaceutical, Prescription Technology Solutions (RxTS), Medical-Surgical Solutions, and International. The U.S. Pharmaceutical segment distributes branded, generic, specialty, biosimilar and over-the-counter pharmaceutical drugs, and other healthcare-related products. This segment also provides practice management, technology, clinical support, and business solutions to community-based oncology and other specialty practices; and consulting, outsourcing, technological, and other services, as well as sells financial, operational, and clinical solutions to pharmacies. The RxTS segment serves biopharma and life sciences partners and patients to address medication challenges for patients by working across healthcare; connects patients, pharmacies, providers, pharmacy benefit managers, health plans, and biopharma companies to deliver innovative solutions to help people get the medicine needed to live healthier lives; and provides prescription price transparency, benefit insight, dispensing support, third-party logistics, and wholesale distribution support services. The Medical-Surgical Solutions segment provides medical-surgical supply distribution, logistics, and other services to healthcare providers, including physician offices, surgery centers, nursing homes, hospital reference labs, and home health care agencies. The International segment offers distribution and services to wholesale, institutional, and retail customers in Europe and Canada. McKesson Corporation was founded in 1833 and is headquartered in Irving, Texas.
Merck & Co., Inc. logo

Merck & Co., Inc.

NYSE:MRK
Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. The company serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. It has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics LP; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV, as well as a collaboration with Bionomics to identify novel a7 nAChR PAMs suitable for the treatment of cognitive disorder; and clinical trial collaboration and supply agreement with Ankyra Therapeutics to evaluate ANK-101 in combination with KEYTRUDA (pembrolizumab) in patients with advanced solid tumors, as well as a clinical trial collaboration and supply agreement with Phanes Therapeutics, Inc. to evaluate PT886 in combination with KEYTRUDA for the treatment of claudin 18.2 positive gastric or gastroesophageal junction adenocarcinomas, as well as a development and commercialization agreement with Daiichi Sankyo Company, Limited to jointly develop and commercialize Daiichi Sankyo's DXd antibody drug conjugate (ADC) candidates and a collaboration with HiberCell, Inc. Merck & Co., Inc. was founded in 1891 and is headquartered in Rahway, New Jersey.
Pfizer logo

Pfizer

NYSE:PFE
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Retacrit, Lorbrena, and Braftovi brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc., as well as strategic partnership with CSPC Pharmaceutical Group Limited to launch a local brand of the COVID-19 oral therapeutic treatment Nirmatrelvir/Ritonavir in China, and a collaboration with Carrick Therapeutics Limited. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

SPDR S&P Pharmaceuticals ETF

NYSEARCA:XPH
SPDR S&P Pharmaceuticals ETF (the Fund) seeks to replicate as closely as possible the total return performance of the S&P Pharmaceuticals Select Industry Index. The S&P Pharmaceuticals Select Industry Index represents the pharmaceuticals sub-industry portion of the S&P Total Markets Index. The S&P TMI tracks all the United States common stocks listed on the New York Stock Exchange, American Stock Exchange, National Association of Securities Dealers Automated Quotation (NASDAQ) National Market and NASDAQ Small Cap exchanges. The Fund invests substantially all, but at least 80%, of its total assets in the securities comprising the Index. In addition, the Fund may invest in equity securities that are not included in the Index, cash and cash equivalents or money market instruments, such as repurchase agreements and money market funds. The Pharmaceuticals Index is a modified equal weight index. SSgA Funds Management, Inc. is the Fund's investment advisor.

My Account -